Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

Impact · against what's priced in

Junshi Biosciences' positive Phase 3 NEOTORCH results for perioperative toripalimab provide a catalyst for expanding the drug's indication into resectable stage II-III NSCLC. This successful final analysis supports future regulatory filings and increases the addressable patient population for the company's core oncology franchise.

1877+0.80: No priced-in read yet

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

What matters in this story

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

What matters in this story

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

How each ticker is affected

Track these names every morning.

ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

What matters in this story

Next reads from the same story arc

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

What matters in this story

Next reads from the same story arc

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

How each ticker is affected

Track these names every morning.

ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study